- Home
- DMAC vs OBT Comparison
DMAC vs OBT Comparison
Compare DMAC & OBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- OBT
- Stock Information
- Founded
- DMAC 2000
- OBT 1892
- Country
- DMAC United States
- OBT United States
- Employees
- DMAC N/A
- OBT N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- OBT Major Banks
- Sector
- DMAC Health Care
- OBT Finance
- Exchange
- DMAC Nasdaq
- OBT Nasdaq
- Market Cap
- DMAC 310.1M
- OBT 368.1M
- IPO Year
- DMAC N/A
- OBT N/A
- Fundamental
- Price
- DMAC $7.06
- OBT $24.45
- Analyst Decision
- DMAC Strong Buy
- OBT Buy
- Analyst Count
- DMAC 3
- OBT 1
- Target Price
- DMAC $12.33
- OBT $29.00
- AVG Volume (30 Days)
- DMAC 262.5K
- OBT 23.1K
- Earning Date
- DMAC 11-12-2025
- OBT 10-29-2025
- Dividend Yield
- DMAC N/A
- OBT 2.13%
- EPS Growth
- DMAC N/A
- OBT 18.38
- EPS
- DMAC N/A
- OBT 3.03
- Revenue
- DMAC N/A
- OBT $115,418,000.00
- Revenue This Year
- DMAC N/A
- OBT $18.34
- Revenue Next Year
- DMAC N/A
- OBT $6.14
- P/E Ratio
- DMAC N/A
- OBT $8.08
- Revenue Growth
- DMAC N/A
- OBT 17.75
- 52 Week Low
- DMAC $3.19
- OBT $20.97
- 52 Week High
- DMAC $7.49
- OBT $33.06
- Technical
- Relative Strength Index (RSI)
- DMAC 57.38
- OBT 48.55
- Support Level
- DMAC $6.64
- OBT $23.25
- Resistance Level
- DMAC $7.13
- OBT $24.79
- Average True Range (ATR)
- DMAC 0.27
- OBT 0.83
- MACD
- DMAC -0.00
- OBT 0.02
- Stochastic Oscillator
- DMAC 77.21
- OBT 66.03
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About OBT Orange County Bancorp Inc.
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.